Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GEHC.MX
BUYGE HealthCare Technologies Inc. · Healthcare · United States · $27.5B · Avg Vol: $9K/d
COMPANY DESCRIPTION
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.3B | 19.6B | 19.7B | 20.6B | 4.0% | 21.0B | 21.8B | 22.8B | 5.1% |
| EPS | 4.63 | 3.05 | 4.37 | 4.56 | -0.5% | 4.17 | — | — | — |
| Shares | 454.0M | 455.3M | 457.0M | 455.7M | +0.4% | 454.9M | — | — | — |
| Debt | 8.6B | 9.9B | 9.4B | 10.5B | 6.6% | 10.6B | — | — | — |
| Equity | 9.4B | 7.1B | 8.4B | 10.4B | 3.5% | — | — | — | — |
| Op CF | 2.1B | 2.1B | 2.0B | 2.0B | -2.0% | 2.0B | — | — | — |
| Inv CF | -398.0M | -558.0M | -914.0M | -1.0B | — | — | — | — | — |
| Fin CF | -822.0M | -478.0M | -573.0M | 617.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GEHC.MX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GEHC.MX | GE HealthCare Technologies Inc.(you) | $27.5B | 67 | BUY |
| DXCM | DexCom, Inc. | $27.6B | 83 | STRONG BUY |
| EW | Edwards Lifesciences Corporation | $47.6B | 72 | BUY |
| STE | STERIS plc | $20.9B | 81 | STRONG BUY |
| BSX.MX | Boston Scientific Corporation | $66.0B | 63 | HOLD |
| BIO | Bio-Rad Laboratories, Inc. | $8.4B | 63 | HOLD |
| PEN | Penumbra, Inc. | $12.5B | 53 | HOLD |
| BRKR | Bruker Corporation | $9.2B | 59 | HOLD |
| SYK | Stryker Corporation | $126.6B | 67 | BUY |
| ZBH | Zimmer Biomet Holdings, Inc. | $17.7B | 91 | STRONG BUY |
Peer medians: ROE -25.6% · P/E 27.9x · Gross margin 50.7%